Role of RORgt+ (note: g: is gamma symbol) lymphocytes in Gut Tissue Homeostasis

RORgt(注:g:是伽玛符号)淋巴细胞在肠道组织稳态中的作用

基本信息

  • 批准号:
    10456906
  • 负责人:
  • 金额:
    $ 56.05万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-08-01 至 2026-07-31
  • 项目状态:
    未结题

项目摘要

Project Summary/Abstract: ILC3s, gdT17 and Th17 cells share common features, e.g., expressing the master transcription factor RORgt and the effector cytokines IL-17A, IL-17F and IL-22, and perform distinct immune functions under different environment context. Our preliminary data suggest that RORgt+ cell-intrinsic deletion of Tfam in Tfamfl/flRorc- cre mice affected RORgt+ gdT17 cells and ILC3s in vivo maintenance and led to small intestinal tissue remodeling via a tuft cell–ILC2 circuit. An emerging concept of mitochondrial control of immunity beyond ATP generation has recently been proposed. Based on the premise and our preliminary data, we hypothesize that that Tfam-mediated mitochondrial respiration in gdT17 cells and ILC3s is pivotal for gdT17/ILC3 cell homeostasis and regulation of small intestine tissue remodeling/metabolic changes and immunity/inflammation. Specifically, we will investigate 1) the role of Tfam in gdT17 and ILC3 lymphocyte maintenance, 2) the role of Tfam in gdT17 cells and/or ILC3s in regulating tuft cell-ILC2 circuit and small intestine tissue remodeling, and 3) the role of Tfam in gdT17 cells and/or ILC3s in regulation of microbiome and small intestinal immunity and inflammation. These experiments will offer an opportunity to elucidate Tfam- mediated mitochondrial respiration in RORgt+ lymphocytes in the small intestine under the steady state and during infection/immunity. Our study will provide novel cellular and molecular insights into the maintenance and function of gdT17 cells and ILC3s regulated by Tfam. Understanding the mechanisms underlying the requirement of Tfam for RORgt+ cells in regulation of small intestine tissue remodeling and immunity may represent a new paradigm for human disease treatment and/or prevention.
项目总结/文摘:

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Liang Zhou其他文献

Liang Zhou的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Liang Zhou', 18)}}的其他基金

Role of RORgt+ (note: g: is gamma symbol) lymphocytes in Gut Tissue Homeostasis
RORgt(注:g:是伽玛符号)淋巴细胞在肠道组织稳态中的作用
  • 批准号:
    10295887
  • 财政年份:
    2021
  • 资助金额:
    $ 56.05万
  • 项目类别:
Role of RORgt+ (note: g: is gamma symbol) lymphocytes in Gut Tissue Homeostasis
RORgt(注:g:是伽玛符号)淋巴细胞在肠道组织稳态中的作用
  • 批准号:
    10669088
  • 财政年份:
    2021
  • 资助金额:
    $ 56.05万
  • 项目类别:
Regulation of Gut Innate Lymphoid Cells by Ahr
Ahr 对肠道先天淋巴细胞的调节
  • 批准号:
    10187510
  • 财政年份:
    2017
  • 资助金额:
    $ 56.05万
  • 项目类别:
Regulation of Gut Innate Lymphoid Cells by Ahr
Ahr 对肠道先天淋巴细胞的调节
  • 批准号:
    10734895
  • 财政年份:
    2017
  • 资助金额:
    $ 56.05万
  • 项目类别:
Regulation of Gut Innate Lymphoid Cells by Ahr
Ahr 对肠道先天淋巴细胞的调节
  • 批准号:
    9361647
  • 财政年份:
    2017
  • 资助金额:
    $ 56.05万
  • 项目类别:
ROLE OF AHR IN T LYMPHOCYTE DEVELOPMENT AND FUNCTION
AHR 在 T 淋巴细胞发育和功能中的作用
  • 批准号:
    9148191
  • 财政年份:
    2015
  • 资助金额:
    $ 56.05万
  • 项目类别:
Role of Ahr in T Lymphocyte Development and Function
Ahr 在 T 淋巴细胞发育和功能中的作用
  • 批准号:
    9028639
  • 财政年份:
    2015
  • 资助金额:
    $ 56.05万
  • 项目类别:
ROLE OF AHR IN T LYMPHOCYTE DEVELOPMENT AND FUNCTION
AHR 在 T 淋巴细胞发育和功能中的作用
  • 批准号:
    9768468
  • 财政年份:
    2015
  • 资助金额:
    $ 56.05万
  • 项目类别:
ROLE OF AHR IN T LYMPHOCYTE DEVELOPMENT AND FUNCTION
AHR 在 T 淋巴细胞发育和功能中的作用
  • 批准号:
    9319753
  • 财政年份:
    2015
  • 资助金额:
    $ 56.05万
  • 项目类别:
ROLE OF AHR IN T LYMPHOCYTE DEVELOPMENT AND FUNCTION
AHR 在 T 淋巴细胞发育和功能中的作用
  • 批准号:
    9208952
  • 财政年份:
    2015
  • 资助金额:
    $ 56.05万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 56.05万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 56.05万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 56.05万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 56.05万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 56.05万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 56.05万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 56.05万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 56.05万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 56.05万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 56.05万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了